Clinical Focus

  • Internal Medicine
  • Solid Organ Transplant
  • Cystic Fibrosis
  • Pulmonary Hypertension

Academic Appointments

Professional Education

  • Associate medical Director, Stanford University School of Medicine, Stanford, CA (2013)
  • Consultant Heart Transplant Unit, Kaiser Permanente Santa Clara Medical Center,, Santa Clara, CA (2011)
  • Fellowship, PAH, Stanford University School of Medicine, Stanford, CA (2011)
  • Fellowship Heart Transplant, Stanford University School of Medicine, Stanford, CA (2010)
  • Fellowship:Stanford University School of Medicine (2010) CA
  • Residency:Highland General Hospital (2009) CA
  • Fellowship Genetics of Obesity, University of California, San Francisco, San Francisco, CA (2006)
  • Emergency Department Attending, Hôpital Saint-Michel, France, Paris (2003)
  • Residency, Universite De Paris Faculte De Medecine Necker-Enfants Malade, France, Paris (2003)
  • Hygiene and microbiology teacher, Medical Secretary School, France, Paris (2002)
  • Medical Education, Universite De Paris Faculte De Medecine Necker-Enfants Malade, France, Paris (2000)
  • Engineering School, Lycée Saint Louis, France, Paris (1992)


Journal Articles

  • Evidence-Based Management of Right Heart Failure: a Systematic Review of an Empiric Field REVISTA ESPANOLA DE CARDIOLOGIA Skhiri, M., Hunt, S. A., Denault, A. Y., Haddad, F. 2010; 63 (4): 451-471


    In recent years, several studies have shown that right ventricular function is an important predictor of survival in patients with congenital heart disease, pulmonary hypertension or left heart failure. Our understanding of right heart failure has improved considerably over the last two decades. In this review article, our objective was to provide a critical summary of the evidence underlying the management of right heart failure. A systematic review of the literature was performed using PubMed and the latest issue of the Cochrane Central Register of Controlled Trials to identify studies conducted between January 1975 and January 2010. The literature search encompassed observational studies, randomized controlled trials and meta-analyses. The evidence underlying the use of beta-blockade, angiotensin-converting enzyme inhibitors, inhaled nitric oxide, hydralazine, warfarin, and resynchronization therapy in right heart failure was systematically reviewed. Emerging new therapies, such as metabolic modulators, and the pearls and pitfalls of managing right heart failure are also discussed in the article.

    View details for Web of Science ID 000276217300011

    View details for PubMedID 20334811

Stanford Medicine Resources: